Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 31;13(12):3815-3818.
doi: 10.21037/tlcr-24-844. Epub 2024 Dec 27.

Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer

Marie-Frédérique D'Amours  1 , Cheryl Ho  1
Affiliations
Editorial

Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer

Marie-Frédérique D'Amours et al. Transl Lung Cancer Res. .
No abstract available

Keywords: ALK inhibitor; Lung cancer; alectinib; anaplastic lymphoma kinase (ALK); early-stage non-small cell lung cancer (early-stage NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-844/coif). M.F.D.A. declares honoraria to self for an educational presentation from Pfizer. C.H. declares grant funding from Roche and AstraZeneca paid to institution and honaria paid to self from Abbvie, Amgen, AstraZeneca, Bayer, BMS, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, and Sanofi. The authors have no other conflicts of interest to declare.

Comment on

  • Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.

References

    1. Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2024;390:1265-76. 10.1056/NEJMoa2310532 - DOI - PubMed
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Yue D, Xu S, Wang Q, et al. Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:3912-7. 10.1200/JCO.22.00428 - DOI - PubMed
    1. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015;33:4007-14. 10.1200/JCO.2015.61.8918 - DOI - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed

LinkOut - more resources